Histamine in allergic diseases: an old molecule in new concepts by HASH(0x7fe9909d7a10)
  
 
Summary of Ph.D. Thesis 
 
 
 
 
 
HISTAMINE IN ALLERGIC DISEASES: 
AN OLD MOLECULE IN NEW CONCEPTS 
 
 
 
 
 
 
Edina Garaczi M.D. 
 
 
 
 
 
 
 
Supervisor: 
Prof. Lajos Kemény M.D., D.Sc. 
 
 
 
 
 
 
Department of Dermatology and Allergology 
Albert Szent-Györgyi Clinical Center 
University of Szeged 
 
 
 
2011 
 
 
  
1 
1. INTRODUCTION 
 
 
Histamine has been established to play a pathophysiological regulatory role 
in various immunological reactions. The main functions of histamine 
include H1 receptor (H1R) mediated actions on smooth muscle, vascular 
permeability and modulation of allergic response, and gastric acid secretion 
basically via H2 receptors (H2R). H3 receptor (H3R) is expressed in the 
nervous system, where it serves as a presynaptic feedback receptor on 
histaminergic neurons. H4 receptor (H4R), the last receptor discovered, is 
largely expressed in haemopoietic cells and its chemotactic properties 
designate its regulatory role in immunomodulation. Highly selective 
blockers and agonists suitable for in vitro and in vivo use have been 
developed for these histamine receptors. These include clinically 
established H1R and H2R blockers, as well as novel investigational drugs 
directed toward H4R. 
Histamine is a diamine derivate of histidine that is produced under 
the control of a single enzyme, histidine decarboxylase (HDC). HDC 
deficient (HDC-/-) mice were generated by Ohtsu and his co-workers about 
a decade ago. Destruction of the HDC gene results in a marked reduction of 
the tissue histamine content. These HDC-/- mice represent a suitable 
experimental model to assess the role of histamine in allergic diseases. 
In the first part of our present work, we investigated the 
immunoregulatory role of histamine using HDC-/- mice in a highly 
prevalent allergic disease, in contact dermatitis. 
Allergic rhinitis is a common inflammatory disease that causes 
major illness and disability worldwide. The prevalence of AR was found to 
be around 25% in a study on the general population in Europe. The central 
role of histamine in the pathophysiology of allergic rhinitis is well 
established.  
In the second part of this work we compared the efficacy of a 
second generation antihistamine, fexofenadine HCl with a newly developed 
phototherapeutic modality in patients with allergic rhinitis. 
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2. AIMS 
 
 
2.1. To investigate the role of histamine in contact hypersensitivity 
 
1. We compared the CHS response in HDC-/- mice with that of in wild type 
mice 
 
2. We measured the cell composition of the axillary and inguinal lymph 
nodes 
 
3. We measured the composition of infiltrating cells in the ear skin 
 
4. We measured the expression of IL-2, IFN-γ, TNF-α and IL-4 genes in the 
ear skin 
 
 
 
2.2. To compare the efficacy of fexofenadine HCl, a second generation 
antihistamine with that of a new intranasal phototherapeutic device in 
patients with seasonal allergic rhinitis 
 
1. A randomized open study was conducted in patients with a history of at 
least 2 years of moderate-to-severe ragweed-induced allergic rhinitis. 
 
2. Thirty-one patients were randomly assigned to receive either intranasal 
phototherapy or fexofenadine HCl for 2 weeks. 
 
3. Each patient kept a daily diary of symptoms. Total nasal score (TNS), a 
sum of scores for nasal symptoms (nasal obstruction, itching, rhinorrhea and 
sneezing) was also calculated. 
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3. HISTAMINE IN CONTACT HYPERSENSITIVITY 
 
3.1. INTRODUCTION 
 
Histamine, synthesized by histidine decarboxylase (HDC), is produced 
mainly in mast cells, basophils and histaminerg neurons, but macrophages, 
dendritic cells and T lymphocytes also synthesize histamine. The production 
and release of histamine are modulated by various cytokines such as IL-1, 
IL-3, IL-5 and IL-8. Histamine plays a regulatory role in Th1/Th2 balance 
at multiple points; however, the majority of histamine actions seem to 
promote Th2 responses. 
Contact hypersensitivity (CHS) response develops in two distinct 
phases: sensitization and elicitation. In the sensitization phase, mice 
exposed to contact allergen showed an increase in the percentage of antigen 
(Ag) specific Thy1+/CD5+/CD3-/TCR-/B220+ cells in the skin-draining 
lymph nodes (DLN). These B220+ (CD45R+) B cells produce IgM/IgG type 
antibodies that pass into the circulation and the extravascular tissues. These 
antibodies bind to receptors on the surface of mast cells and platelets and 
play a role in the increase of vascular permeability. Cytokines produced by 
Tc1 cells (IFN-γ), Th1 cells (IL-2, IFN-γ and TNF-α), Th2 cells (IL-4 and 
IL-10) and Langerhans cells (IL-12 and IL-18) are important for the optimal 
induction and initiation of CHS in DLN. 
The elicitation phase is characterized by two distinct phases. In the 
early phase of elicitation, the antigen bound by IgM/IgG type antibodies 
produced by B220+ B cells leads to mast cell and platelet activation. Release 
of serotonin and TNF-α from these cells results in an increased vascular 
permeability. Geba et al found that delayed type hypersensitivity reaction 
(DTH) was either intact or only partially decreased in mast–cell deficient 
mice, and severe depletion of platelets with anti-platelet antibody strongly 
inhibited the contact hypersensitivity, especially in mast-cell deficient mice. 
These data suggest that serotonin and TNF-α are important mediators in the 
early phase of DTH. 
In the later phase of elicitation (48-72 hours after challenge), 
antigen–specific T cells (αβT cells) are activated, resulting in the 
production of various cytokines. It is known that in the CHS reaction the 
main effector cells are IFN-γ-producing CD8+ Tc1 cells. The CHS 
responses are also regulated by IL-2, IFN-γ and TNF-α-producing CD4+ 
Th1 cells, as well as by IL-4 and IL-10-producing CD4+ Th2 cells. 
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In the present study, we examined the CHS response in HDC 
knockout (HDC-/-) histamine deficient mice. These mice were generated 
using a gene targeting method by Ohtsu et al. HDC-/- mice exhibit a 
decreased number of mast cells. The lack of histamine leeds to a large 
reduction in the overall contents of mast cell secretory granules, including 
proteases MMCP4, MMCP5 (chymases) and MMCP6 (tryptase). In HDC-/- 
mice, plasma extravasation could not be observed after passive cutaneous 
anaphylaxis test, suggesting that histamine plays a significant role not only 
in the anaphylactic increase of vascular permeability but also in the negative 
regulation of neutrophil infiltration. 
The purpose of the present study was to determine the 
immunoregulatory role of histamine in dinitrofluorobenzene (DNFB)-
induced delayed type hypersensitivity. We found, that the lack of histamine 
caused an intense Th1 type response, suggesting that histamine plays a 
negative regulatory role in contact dermatitis 
 
 
 
3.2. RESULTS AND DISCUSSION 
 
HDC-/- mice demonstrated increased contact hypersensitivity to DNFB 
The abdominal skin of the mice was shaved and sensitized with 25 µl 0.5% 
2,4-dinitrofluorobenzene in acetone/olive oil (4/1) for 2 consecutive days 
(days 0 and 1). Five days later, the dorsal surface of both ears was 
challenged with 15 µl 0.2% DNFB (n=6). The control mice were also 
sensitized with DNFB, but their ears were treated with acetone/olive oil 
(n=4).Twenty-four hours after challenge, the DNFB induced increase of the 
ear thickness was significantly higher in the HDC-/- mice than in wild type 
mice. Fourty-eight hours after challenge the ear thickness was still higher in 
HDC-/- mice compared to wild type mice, but the difference was not 
significant between the two groups. 
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The percentages of CD4+ Th and CD8+ Tc cells were lower, those of 
CD45R+ B cells were higher in the DLNs of HDC-/- mice 
No significant difference was observed between the total number of the 
DLN cells in the DNFB treated HDC-/- and wild type mice. The 
percentages of CD3+ T, CD4+ Th and CD8+ Tc were significantly lower in 
the HDC-/- mice. In contrast, the percentage of B220+ (CD45R+) B cells 
was significantly higher in the HDC-/- mice than in the wild type mice. The 
percentages of granulocytes and macrophages did not differ in the two 
groups. 
Similar differences were seen in the cell composition of the axillary 
and inguinal lymph nodes of untreated HDC-/- and wild type mice. The 
percentages of the different cell subpopulations did not differ significantly 
from those found in the appropriate DNFB treated groups. Consequently 
these differences do not seem to be due to the DNFB treatment, but they are 
rather associated with the lack of histamine in HDC-/- mice. 
 
 
The number of infiltrating cells was higher in the ear specimens of 
HDC-/- mice 
Histologic sections were made from the ears 24 and 48 hours after 
challenge. In contrast to the acetone/olive-treated ear specimens, in the 
DNFB painted ears of both HDC-/- and wild type mice a cellular infiltrate 
and edema was seen. The majority of the infiltrating cells were neutrophil 
granulocytes and mononuclear cells in both DNFB treated groups at 24 and 
48 hours after challenge, but the number of infiltrating cells and the degree 
of edema was higher in the HDC-/- mice. 
Using HDC-/- mice Hirasawa et al found that histamine plays a 
negative regulatory role for the neutrophil infiltration via H2R receptor in 
allergic inflammation. It has been reported that in the skin of HDC-/- mice 
the expression of H1R and H2R receptors is very sensitive to histamine 
levels and both receptors are downregulated in the skin of HDC-/- mice. 
These results suggest that histamine might inhibit neutrophil infiltration in 
wild-type mice via H2R receptors and the lack of histamine favors a strong 
granulocyte and macrophage infiltration in HDC-/- mice 
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Strong CD45+ leukocyte infiltration was observed in the ears of HDC-/- 
mice 
We observed a significantly higher percentage of CD45+ leukocytes in the 
dermis of the ears of the HDC-/- mice than in that of wild type mice, using 
immunohistochemistry. The number of CD3+ T cells was not increased in 
the DNFB-painted ears compared to the acetone treated ones in either 
group. 
 
 
IL-2, IFN-γ, TNF-α and IL-4 mRNA expression was examined by real-
time RT-PCR 
The expression of IL-2, IFN-γ, TNF-α and IL-4 genes was examined by 
optimized real-time RT-PCR reactions in the ear samples obtained at 24 and 
48 hours after challenge. 
In wild type mice, IL-2 mRNA was undetectable, in contrast with 
this HDC-/- mice constitutively expressed a detectable level of IL-2 mRNA. 
In the HDC-/- mice, DNFB treatment caused a more than 8-fold increase in 
the level of IL-2 mRNA 24 hours after challenge, however, the quantity of 
IL-2 mRNA decreased 48 hours after challenge. In contrast with this, in 
wild type mice, IL-2 mRNA was not detected 24 hours after challenge and 
it reached a detectable level only 48 hours after challenge. 
The IFN-γ mRNA level showed a significantly higher increase in 
HDC-/- mice than in wild type mice 24 hours after challenge. 48 hours after 
challenge, the IFN-γ mRNA level decreased in HDC-/- mice, while 
increased in wild type mice. 
The HDC-/- mice constitutively expressed a detectable level of 
TNF-α, while in wild type mice TNF-α was undetectable. The increase in 
TNF-α expression was 7-fold in HDC-/- mice 24 hours after the DNFB 
treatment, and approximately 3.5-fold higher 48 hours after challenge. In 
the wild type mice, TNF-α mRNA was not detected 24 hours after the 
treatment, and showed an increase 48 hours after challenge. 
The expression of IL-4 mRNA reached a detectable level in HDC-
/- mice but not in wild type mice. The DNFB treatment of HDC-/- mice 
produced a moderate increase of IL-4 mRNA expression 24 hours after 
challenge, and the increase in IL-4 mRNA expression was 5-fold 48 hours 
after the treatment compared to the 24-hour data. In the wild type mice, IL-
4 mRNA was not demonstrated 24 hours after challenge, but a detectable 
amount of mRNA appeared 48 hours after the DNFB treatment. 
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We observed a very early Th1 cytokine response in HDC-/- mice, 
followed by the increased levels of IL-2, IFN-γ and TNF-α mRNAs 24 
hours after DNFB challenge. In these mice, the high levels of Th1 cytokines 
might contribute to the very early increase of the ear thickness and the 
inflammatory response demonstrated by immunohistology. 
Histamine is known to inhibit Th1 lymphocyte functions such as 
production of IL-2, IFN-γ via H2R receptors, and to enhance Th1-type 
responses by triggering the H1R receptors. Fitzsimons et al demonstrated 
that in the skin of HDC-/- mice the H1R and H2R receptors are 
downregulated which might be due to the prolonged histamine deficiency. 
We found a very early and high Th1 cytokine response after antigen 
challenge that might be caused by histamine deficiency. These data indicate 
that endogenous histamine can downregulate the CHS reaction via H2R 
receptor in wild type mice. The lack of histamine causes a downregulation 
of the H2R receptors in HDC-/- mice thereby leading to a higher Th1 
cytokine response compared to wild type mice. These results suggest that in 
the histamine deficient mice, the Th1/Th2 balance is modulated towards 
Th1 dominancy. 
In our study, we demonstrated that histamine is involved in the 
regulation of delayed type hypersensitivity. Using histamine deficient mice 
we showed, that histamine plays a suppressive immunoregulatory role in the 
DNFB induced CHS response.  
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4. INTRANASAL PHOTOTHERAPY  
IN SEASONAL ALLERGIC RHINITIS 
 
 
4.1. INTRODUCTION 
 
Allergic rhinitis is a common inflammatory disease that causes major illness 
and disability worldwide. The prevalence of AR was found to be around 
25% in a study on the general population in Europe. 
We recently showed that intranasal phototherapy is an effective 
treatment for allergic rhinitis (AR). Rhinophototherapy with low doses of 
mixed ultraviolet and visible light significantly improve the clinical 
symptoms of AR by acting at multiple points such as induction of T-cell 
and eosinophil apoptosis and suppression of release of mediators like 
eosinophil cationic protein and interleukin 5. 
Guidelines issued by the Allergic Rhinitis and its Impact on 
Asthma (ARIA) group recommend the use of second generation 
antihistamines as first-line treatment for AR. The newer-generation oral 
antihistamines such as desloratadine, fexofenadine and levocetirizine have 
demonstrated efficacy in reducing the symptoms of AR, including 
rhinorrhea, nasal itching and sneezing, and in some clinical studies nasal 
congestion. Fexofenadine is a non-sedating antihistamine, has a rapid onset 
and a long duration of action. In addition to blocking H1 receptors, it has 
been shown to reduce allergic inflammatory responses mediated by mast 
cells, basophils, epithelial cells, eosinophils and lymphocytes. 
The use of second-generation antihistamines in the treatment of 
seasonal allergic rhinitis (SAR) is well established. However, in clinical 
practice, SAR symptoms are not always satisfactory controlled by 
medication and some patients fail to respond to treatment. A new 
phototherapeutic device has been developed at the University of Szeged, 
emitting a combination of low dose UVB, UVA and visible light for the 
treatment of allergic rhinitis. The aim of this pilot study was to compare the 
efficacy of intranasal phototherapy with that of the new generation 
antihistamine, fexofenadine HCl in seasonal allergic rhinitis. 
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4.2. MATERIALS AND METHODS 
Patients and study design 
A randomized open study was conducted in patients with a history of at 
least 2 years of moderate to severe ragweed-induced allergic rhinitis. 
Positive skin prick test results and an elevated level of ragweed-specific IgE 
antibody confirmed the diagnosis. The Ethical Committee of University of 
Szeged approved the protocol. All patients gave their written informed 
consent. 
The patients were enrolled after the beginning of the ragweed 
season, when the pollen counts were higher than 50/m3 in the Szeged area. 
Thirty-one patients with moderate-to-severe symptoms were randomly 
assigned to receive either intranasal phototherapy (5% UVB, 25% UVA and 
70% visible light) 3 times a week for 2 weeks (n=18), or 180 mg 
fexofenadine HCl per day for 2 weeks (n=13), with a randomization ratio of 
3 to 2. Each intranasal cavity was treated with gradually increasing doses 
(starting dose: 1.08 J/cm2, maximal dose: 1.62 J/cm2), the irradiations were 
performed with the Rhinolight 180 mW lamp (Rhinolight Ltd, Szeged, 
Hungary). The dose was raised by 0.27 J/cm2 at every second treatment. 
Each patient kept a daily diary of symptoms on a scale of 0 to 3 (0 
indicating no symptoms and 1, 2, 3 indicating mild, moderate and severe 
symptoms, respectively) for nasal obstruction, nasal itching, rhinorrhea, 
sneezing and palate itching during the treatment. Total nasal score (TNS), a 
sum of scores for nasal symptoms (nasal obstruction, itching, rhinorrhea and 
sneezing) was also calculated. 
 
Statistical analysis 
Repeated measures ANOVA test was used to assess the statistical 
significance of clinical symptom changes and the overall efficacy. The post 
hoc analysis (Dunnett test) revealed the differences between the time points 
in each treatment group. The percentage changes from baseline in TNS 
were compared using Fisher exact two tailed test. Value of P<0.05 was 
considered statistically significant. 
 
4.3. RESULTS 
Eighteen patients (12 women, 6 men; ages ranged from 18 to 58 years, 
mean age: 40.67) received intranasal phototherapy and thirteen patients (8 
women, 5 men; ages ranged from 18 to 55 years, mean age: 40.00) received 
180 mg fexofenadine HCl per day. The 2 groups did not differ significantly 
in TNS at the beginning of treatment period (P=0.236). The baseline TNS 
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(mean±SD) was 8.61±2.64 in the rhinophototherapy group, and 7.46±2.57 
in the fexofenadine HCl group. 
In all of the parameters the scores decreased significantly at the end 
of treatment compared with day 1 for all of the parameters: sneezing 
(P=0.0002), rhinorrhea (P=0.0004), nasal itching (P=0.0003), nasal 
obstruction (P=0.0014) and palate itching (P=0.00002). In the fexofenadine 
HCl group none of the symptoms improved significantly (P> 0.05) at the 
end of the study except sneezing (P=0.007). TNS was significantly 
decreased in the rhinophototherapy group (P<0.0001), but no significant 
difference was observed in the fexofenadine HCl group after 2 weeks of 
treatment compared to the baseline (P=0.35). 
When we compared the two treatment groups, we did not find 
significant differences in any of the parameters between the 
rhinophototherapy group and the fexofenadine HCl group. However, the 
improvement in the rhinitis symptoms was more pronounced in the 
rhinophototherapy group compared to the fexofenadine HCl group, but this 
difference was not statistically significant at the end of the study. 
We assessed the changes from baseline in TNS at the end of the 
study. TNS-25, TNS-50 and TNS-75 correspond to the percentages of 
responders at day 14 with TNS improvement of more than 25%, 50% and 
75%, respectively. If the patient’s TNS was reduced by less than 25%, the 
patient was classified as nonresponder. 
After 2 weeks of intranasal phototherapy, there were 15 patients 
(83.3%) with more than 25% improvement in TNS and 11 patients (61.1%) 
with more than 50% improvement in TNS compared to the baseline. In 
contrast to this only 4 patients (30.8%) exhibited more than 25% 
improvement in TNS and 2 patients (15.4%) showed more than 50% 
improvement in TNS in the fexofenadine HCl group after last treatment. We 
found that the ratio of patients with both TNS-25 (P=0.0075) and TNS-50 
(P=0.025) were significantly higher in the rhinophototherapy group 
compared to the fexofenadine HCl group. There was no significant 
difference in TNS-75 between the two groups. 
Intranasal phototherapy was overall well tolerated. The only side 
effect was dryness of the nasal mucosa, which occurred in all patients in the 
rhinophototherapy group and in two patients in the fexofenadine HCl group. 
All patients scored the dryness as mild except one in the rhinophototherapy 
group, and were controlled by emollients. In the case of this patient in the 
rhinophototherapy group one treatment was skipped. All patients completed 
the study. 
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4.4. DISCUSSION 
 
In this pilot study, we found that intranasal phototherapy is more effective 
than fexofenadine HCl in reducing clinical symptoms in patients with 
moderate-to-severe SAR. In the rhinophototherapy group, all symptoms 
improved significantly, in contrast to this none of the scores decreased 
significantly in the fexofenadine HCl group at the end of the 2 weeks of 
treatment, except sneezing. 
Second generation antihistamines are recommended as first-line 
therapy for seasonal allergic rhinitis. In randomized studies with great 
number of patients fexofenadine HCl exhibited significant improvement in 
SAR. The low number of patients involved in our study may account for the 
results obtained for the fexofenadine HCl group. However, the efficacy of 
rhinophototherapy in reducing majority of symptoms associated with SAR 
suggests a more powerful treatment effect. 
The mechanism of action involved in the therapeutic effect of 
rhinophototherapy was investigated in previous studies. We have also 
published that nasal mucosa exposed to UV light possess the capacity to 
repair DNA damage. Nasal dryness induced by allergic inflammation occurs 
in patients with active symptoms of rhinitis. However, higher number of 
patients with mild dryness of the nasal mucosa was observed after 
rhinophototherapy compared to the fexofenadine HCl treatment. We are 
currently investigating the drying effect of UV with different wavelength on 
the nasal mucosa. Further studies are needed to define the therapeutic 
potential of intranasal phototherapy and to determine its application as 
chronic treatment for perennial allergic rhinitis and possibly to other 
inflammatory diseases. 
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5. CONCLUSION 
 
Since its discovery at the beginning of the 20th century, histamine has been 
established to play a key pathophysiological regulatory role in various 
immunological functions. However, the precise role of histamine is still 
uncertain. In the last couple of years the role of endogenous histamine has 
been extensively studied in allergy, asthma, and various autoimmune 
diseases using histamine deficient mice. 
 Histidine decarboxylase deficient (HDC-/-) mice were developed 
about a decade ago by Ohtsu et al. In these mice the levels of histamine in 
various tissues are much lower than those in wild type mice. We at first 
expected that the contact hypersensitivity response would be suppressed in 
HDC-/- mice. Surprisingly we found that the DNFB induced CHS is more 
intense in histamine deficient mice than in wild type mice. We provided 
here the first evidence that histamine can regulate negatively the 
immunologic response in contact dermatitis. In accordance with our results, 
the negative regulatory functions of endogenous histamine have been 
recently reported by other research groups using experimental animal 
models with various allergic and autoimmune diseases. 
 In our study we used HDC-/- mice and we demonstrated that 
histamine plays a negative regulatory role in contact hypersensitivity 
response. 
 
Allergic rhinitis is the most frequent allergic disease affecting 10-20% of 
the population worldwide. Second generation antihistamines are the first-
line treatments in AR, however the treatment of allergic rhinitis is 
occasionally unsatisfactory and some patients fail to respond to the 
treatment. Using experimental mouse models, it has been shown that H1R 
antagonists failed to completely suppress nasal allergic symptoms. 
 In our present work, we compared the efficacy of a second 
generation antihistamine with that of a new therapeutic device intranasal 
phototherapy in seasonal allergic rhinitis. Intranasal phototherapy or 
rhinophototherapy has been recently developed emitting combined UVA, 
UVB and visible light at the University of Szeged. Previously, 
rhinophototherapy has been shown to be effective in controlling rhinitis 
symptoms in moderate-to-severe SAR. Here we showed that intranasal 
phototherapy may be an alternative treatment for patients with allergic 
rhinitis not controlled by antihistamines. 
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In summary, the pathophysiological role of histamine in immunoregulation 
is a much more complex story than expected. New evidences about the 
diverse functions of endogenous histamine and its receptors can offer an 
optimistic perspective for novel therapeutics. 
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